News Abivax

Equities

ABVX

FR0012333284

Real-time Euronext Paris Other stock markets 06:33:10 2024-04-26 am EDT			5-day change	1st Jan Change
14.58 ^EUR	-1.09%		+2.97%	+48.47%

Apr. 11	Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating	MT
Apr. 08	Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating	Apr. 11	MT
Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024	Apr. 08
Abivax publishes financial reports with the French and U.S. securities regulatory agencies	Apr. 08	AQ
Abivax publishes financial reports with the French and U.S. securities regulatory agencies	Apr. 05	EQ
ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Abivax reports 2023 financial results and operational update	Apr. 02	EQ
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn's and Colitis Organization (ECCO)	Feb. 14	AQ
Abivax: presentation on obefazimod at the ECCO congress	Feb. 13	CF
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)	Feb. 13	EQ
ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality	Feb. 07	CI
Abivax appoints new head of quality	Feb. 07	CF
Abivax appoints Ana Sharma as Vice President, Global Head of Quality	Feb. 07	EQ
Transcript : ABIVAX Société Anonyme - Special Call	Feb. 06
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease	Feb. 05	AQ
Abivax Modifies Trial Design of Phase 2b Development Program After US FDA Feedback	Feb. 02	MT
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease	Feb. 02	EQ
Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn?s Disease	Feb. 02	CI
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024	Jan. 24	EQ
Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis	Jan. 24	CI
Abivax: share price rises after strategic update	Jan. 22	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer